VIVUS, Inc. (NASDAQ:VVUS) reported that it has entered into a License and Commercialization Agreement with Sanofi to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States including Russia.